| Title |
Trelagliptin: First Global Approval
|
|---|---|
| Published in |
Drugs, June 2015
|
| DOI | 10.1007/s40265-015-0431-9 |
| Pubmed ID | |
| Authors |
Kate McKeage |
| Abstract |
Trelagliptin (Zafatek(®)) is an orally active dipeptidyl peptidase (DPP)-4 inhibitor developed by Takeda and approved in Japan for the treatment of type 2 diabetes mellitus (T2DM). Unlike other approved agents of its class, which are usually administered once daily, trelagliptin can be administered once weekly. Phase II development of trelagliptin was discontinued in the USA and EU, as Takeda considered that the costs associated with obtaining approval in these markets were prohibitive. This article summarizes the milestones in the development of trelagliptin leading to this first approval for T2DM. |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 18% |
| Student > Bachelor | 3 | 11% |
| Student > Ph. D. Student | 3 | 11% |
| Student > Doctoral Student | 2 | 7% |
| Researcher | 2 | 7% |
| Other | 6 | 21% |
| Unknown | 7 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 5 | 18% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 14% |
| Medicine and Dentistry | 4 | 14% |
| Chemistry | 3 | 11% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Other | 2 | 7% |
| Unknown | 8 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2023.
All research outputs
#7,218,052
of 22,815,414 outputs
Outputs from Drugs
#1,258
of 3,254 outputs
Outputs of similar age
#84,900
of 263,249 outputs
Outputs of similar age from Drugs
#22
of 35 outputs
Altmetric has tracked 22,815,414 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,249 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.